

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
CIN: L24230GJ1993PLC019050



January 17, 2023

Mr. Binoy Yohannan
National Stock Exchange of India Ltd
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.

Sub: Clarification / confirmation on news article appearing in media

Ref: Your letter No. NSE/CM/Surveillance/12738 dated January 16, 2023

Dear Sir,

In response to the query raised by you vide abovementioned letter, we wish to clarify as follows,

1. The news article pertains to inspection carried out by the USFDA at the Halol Facility of Sun Pharmaceutical Industries Limited (“Company”) from April 26, 2022 to May 9, 2022. The Company has filed intimation on USFDA inspection as well as subsequent key developments from time to time and the summary of the event (in chronological order) is as follows.

Sl. No.	Date of Intimation	Particulars of Event
1.	10 May 2022	Intimation of Inspection by USFDA and Form 483 issued with 10 observations
2.	13 August 2022	Intimation of communication by USFDA indicating the inspection classification as “Official Action Indicated” (OAI).
3.	8 December 2022	Intimation of communication by USFDA stating that Halol facility been listed under Import Alert and the explanation by the Company of impact of such alert.
4.	8 December 2022	Intimation of additional details in the form of FAQs on various aspects connected with Import Alert by USFDA.
5.	16 December 2022	Intimation about warning letter issued by USFDA summarising violations with respect to Current Good Manufacturing Practice (cGMP) regulations and also stating that USFDA shall make public the contents of the warning letter in due course.

2. As mentioned in the intimation letter dated 16 December 2022, the warning letter was made public by USFDA on their website on 11 January 2023. The news article dated 14 January 2023, referred by you in your letter mentioned above, appears to be the result of the same and no other event.

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
CIN: L24230GJ1993PLC019050



3. All the developments relating to the news report have been appropriately and timely intimated to the stock exchanges from time to time and we do not believe that there is any other information requiring any intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
4. As mentioned above, this news article is based on an anticipated event which was disclosed by the Company in its intimation dated 16 December 2022 and for which it was mentioned that there is no material impact expected (reference may be drawn to the FAQs filed by the company vide intimation dated 8 December 2022). As such, no material impact of this news article is envisaged on the Company.

We hope that you will find this clarification in order. We shall be happy to provide any further clarification, in case requested.

Yours faithfully,

For **Sun Pharmaceutical Industries Limited**

(Anoop Deshpande)

Company Secretary & Compliance Officer

ICSI Membership No.: A23983